Catalyst Biosciences Inc
NASDAQ:CBIO
Relative Value
There is not enough data to reliably calculate the relative value of CBIO.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
CBIO Competitors Multiples
Catalyst Biosciences Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Catalyst Biosciences Inc
NASDAQ:CBIO
|
289.6m USD | 364.7 | -35.1 | -9.8 | -9.8 | ||
US |
Abbvie Inc
NYSE:ABBV
|
282.8B USD | 5.2 | 58.7 | 12.8 | 19.5 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
163.1B USD | 5.5 | 43.4 | 18.4 | 30.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.8B USD | 11 | 30 | 24.2 | 25.3 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.5B USD | 8.1 | 27.3 | 22.1 | 24.5 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.7 | 27 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81B USD | 3 | 167.4 | 6.7 | 8.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46.5B USD | 9 | -7.8 | -8.5 | -7.5 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 3.3 | 27.5 | 14.1 | 17.6 | ||
KR |
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.3 | 46 | 63.4 |